Publication | Closed Access
A class IA PI3K controls inflammatory cytokine production in human neutrophils
51
Citations
50
References
2011
Year
Inflammatory Lung DiseaseLung InflammationImmunologyImmune RegulationInnate ImmunityImmune SystemInflammationClass Ia Pi3kInflammatory MarkerCell SignalingAutoimmune DiseaseGranulocyteChronic InflammationImmune SurveillanceAutoimmunityImmune FunctionInflammatory DiseaseCell BiologyTnf-activated NeutrophilsCytokineAnti-inflammatoryImmune Cell DevelopmentInflammation BiologyPi3k InhibitionInflammatory Cytokine ProductionPi3k PathwayMedicineHuman Neutrophils
Neutrophils are generally the first leukocytes to arrive at sites of inflammation or injury, where they release a variety of inflammatory mediators, which contribute to shaping the ensuing immune response. Here, we show that in neutrophils exposed to physiological stimuli (i.e. LPS and TNF-α), inhibition of the PI3K signaling pathway impairs the synthesis and secretion of IL-8, Mip-1α, and Mip-1β. Further investigation showed that Mip-1α and Mip-1β gene transcription was similarly decreased, whereas IL-8 transcription and steady-state mRNA levels were unaffected. Accordingly, PI3K inhibition had no impact on NF-κB or C/EBP activation, which are essential for IL-8 transcription, but the basis for this selective inhibition of chemokine transcription remains elusive. We nevertheless identified translational targets of the PI3K pathway (S6, S6 kinase, 4E-BP1). Inhibitor studies and overexpression experiments further established that the various effects of PI3K on chemokine production can be ascribed to p85α and p110δ subunits. Finally, we show that in LPS- and TNF-activated neutrophils, PI3K acts downstream of the kinases p38 MAPK and TAK1. Given the importance of neutrophils and their products in numerous chronic inflammatory disorders, the PI3K pathway could represent an attractive therapeutic target.
| Year | Citations | |
|---|---|---|
Page 1
Page 1